Skip to content
The Policy VaultThe Policy Vault

Revlimid — Medica

Myelodysplastic Syndrome

Initial criteria

  • age ≥ 18 years
  • Patient has symptomatic anemia OR transfusion-dependent anemia OR anemia not controlled with an erythroid stimulating agent

Approval duration

3 years